Patents by Inventor Michael T. Migawa

Michael T. Migawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250154506
    Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one chemical modification.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 15, 2025
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Michael Oestergaard, Mehran Nikan, Graeme C. Freestone, Michael T. Migawa, Brooke A. Anderson, Punit P. Seth, Eric E. Swayze
  • Patent number: 12234447
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: February 25, 2025
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-Hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Publication number: 20240002851
    Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.
    Type: Application
    Filed: January 25, 2023
    Publication date: January 4, 2024
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Brooke A. Anderson, Xue-Hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
  • Publication number: 20230374519
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PMP22 RNA in a cell or animal, and in certain instances reducing the amount of PMP22 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include demyelination, progressive axonal damage and/or loss, weakness and wasting of foot and lower leg muscles, foot deformities, and weakness and atrophy in the hands. Such neurodegenerative diseases include Charcot-Marie-Tooth disease.
    Type: Application
    Filed: June 18, 2021
    Publication date: November 23, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Holly Kordasiewicz, Punit P. Seth, Hien Thuy Zhao, Michael T. Migawa, Ruben E. Valas, Thazha P. Prakash
  • Publication number: 20230159922
    Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.
    Type: Application
    Filed: August 14, 2020
    Publication date: May 25, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael T. Migawa, Graeme C. Freestone
  • Patent number: 11629348
    Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: April 18, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
  • Publication number: 20230068063
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Application
    Filed: March 17, 2022
    Publication date: March 2, 2023
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Publication number: 20220186222
    Abstract: The present disclosure provides oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 16, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Brooke A. Anderson, Xue-hai Liang, William John Drury, III, Michael Oestergaard, Michael T. Migawa, Punit P. Seth
  • Patent number: 11332733
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 17, 2022
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Publication number: 20220064636
    Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside.
    Type: Application
    Filed: October 4, 2019
    Publication date: March 3, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael T. Migawa, Graeme C. Freestone
  • Publication number: 20210380976
    Abstract: The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having one or more chirally enriched phosphorothioate intemucleoside linkages. In certain embodiments, the modified oligonucleotide decreases expression of target mRNA.
    Type: Application
    Filed: October 4, 2019
    Publication date: December 9, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Patent number: 11149264
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 19, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Publication number: 20210261945
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Application
    Filed: February 10, 2021
    Publication date: August 26, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Publication number: 20210254059
    Abstract: The present invention provides gapped oligomeric compounds comprising from 1 to about 3 internucleoside linkages having one of formulas I to XVI. In certain embodiments, inclusion of from 1 to about 3 internucleoside linkages of one of formulas I to XVI, improves selectivity for a target RNA relative to an off target RNA. In certain embodiments, the improved selectivity also provides an improved toxicity profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: June 17, 2019
    Publication date: August 19, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Eric E. Swayze, Punit P. Seth
  • Publication number: 20210054017
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine anaologues.
    Type: Application
    Filed: February 24, 2020
    Publication date: February 25, 2021
    Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
  • Publication number: 20210017513
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Application
    Filed: February 12, 2019
    Publication date: January 21, 2021
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Patent number: 10751419
    Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 25, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10570169
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: February 25, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
  • Patent number: 10450342
    Abstract: Provided herein are methods for removal of monomethoxytrityl groups from oligomeric compounds comprising terminally linked monomethoxytrityl protected amino groups. The present methods differ from standard methods for 5?-dimethoxytrityl removal from oligonucleotides in that the present methods are performed at elevated temperatures and higher pH. In certain embodiments, the present methods provide detritylated oligomeric compounds having a reduced percentage of depurination relative to the same detritylated oligomeric compounds prepared using standard methods. In certain embodiments, the present methods provide an increased rate of detritylation compared to standard methods. In certain embodiments, the modification of the final detritylation step results in an improved yield.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: October 22, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Dana Chreng, Michael T. Migawa
  • Publication number: 20190209694
    Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 11, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze